Welcome to our dedicated page for Teva Pharm SEC filings (Ticker: TEVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Teva Pharmaceutical Industries Limited (TEVA) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8‑K and other key documents filed with the Securities and Exchange Commission. As an issuer with American Depositary Shares listed on the New York Stock Exchange under the symbol TEVA, Teva reports material events, financing arrangements and financial results through these filings.
Recent Form 8‑K filings include items on results of operations and financial condition, where Teva furnishes press releases announcing quarterly financial results for periods such as the quarters ended June 30 and September 30. These filings typically incorporate earnings press releases by reference and clarify that the information is being furnished rather than filed for purposes of the Exchange Act. Another 8‑K describes Teva’s presentation at a major healthcare conference and includes expectations regarding performance for the 2025 fiscal year.
Teva also uses Form 8‑K to disclose material definitive agreements and related direct financial obligations. For example, an 8‑K details the Third Amendment to the Senior Unsecured Sustainability-Linked Revolving Credit Agreement, which extended the maturity date of the revolving facility and amended financial covenants such as the maximum leverage ratio and conditions tied to investment grade status. These filings provide insight into Teva’s capital structure, liquidity management and covenant framework.
On Stock Titan, investors can review these filings alongside AI-powered summaries that explain the main points of each document in plain language. This includes highlighting key terms in credit agreements, summarizing earnings-related disclosures, and pointing out items that may affect leverage, liquidity or future reporting. Users interested in TEVA can use the filings page to track quarterly and annual reporting, current reports on material events, and disclosures related to financing arrangements, while AI tools help interpret lengthy or technical sections of the filings.
Teva Pharmaceutical Industries reported a Form 144 notification for the proposed sale of 62,102 ordinary shares, listed for sale through Citigroup Global Markets Inc. on the NYSE. The shares are identified as rollover/compensation ordinary shares with trade dates listed in March 2026.
Teva Pharmaceutical Industries officer Mark Sabag reported the vesting and settlement of 15,723 restricted share units on March 5, 2026. These units were converted at $0.00 per share into 15,723 ordinary shares, increasing his direct holdings to 287,042 ordinary shares.
Following the transaction, he also held 47,170 restricted share units. The RSUs were originally granted on March 5, 2025, with additional tranches of 15,723 vesting on March 5, 2027 and March 5, 2028, and 15,724 vesting on March 5, 2029. Each RSU represents a right to one ordinary share or its cash value.
Teva Pharmaceutical Industries EVP and CFO Eliyahu Sharon Kalif acquired shares through vested equity awards. On March 5, 2026, he exercised 19,916 Restricted Share Units at $0.00 per unit, converting them into 19,916 Ordinary Shares.
Following the transactions, his reported direct holdings were 59,748 Restricted Share Units and 325,435 Ordinary Shares. The RSUs stem from a March 5, 2025 grant, with additional tranches of 19,916 units scheduled to vest on March 5 of 2027, 2028, and 2029.
Teva Pharmaceutical Industries Chief Accounting Officer Amir Weiss reported equity compensation activity involving restricted share units. On March 5, 2026, 3,537 restricted share units were converted into 3,537 ordinary shares at no cash exercise price as part of a previously granted award.
The footnotes explain this grant was made on March 5, 2025, with 3,537 units vesting on March 5, 2026, 3,537 vesting on each of March 5, 2027 and March 5, 2028, and 3,539 vesting on March 5, 2029. After this transaction, Weiss directly held 30,695 ordinary shares and 10,613 restricted share units.
Teva Pharmaceutical Industries President and CEO Richard Francis reported vesting and related transactions in company equity on March 5, 2026. He exercised 42,452 Restricted Share Units (RSUs), which converted into the same number of ordinary shares at a stated price of $0.00 per share.
Following the RSU conversion, he held 1,190,664 ordinary shares before selling 20,025 ordinary shares in open-market transactions at a weighted average price of $31.6684 per share to cover tax withholding obligations. After these sales, he directly owns 1,170,639 ordinary shares and 127,359 RSUs, each RSU representing a contingent right to one ordinary share or its cash value. The sale was made under a pre-arranged Rule 10b5-1 trading plan. Ordinary shares may be represented by American Depositary Shares on a one-for-one basis.
Teva Pharmaceutical Industries Ltd EVP, U.S. Commercial Christine Fox reported RSU vesting and related share transactions. On March 5, 2026, 17,819 restricted share units were exercised into the same number of ordinary shares at a stated price of $0.00 per share.
On the same date, she sold 7,924 ordinary shares at a weighted average price of $31.6684 per share to cover tax withholding obligations, under a Rule 10b5-1 trading plan adopted on August 11, 2025. Following these transactions, she directly held 84,905 ordinary shares.
Teva Pharmaceutical Industries executive Eric A. Hughes reported equity awards activity and a related share sale. On March 5, 2026, 19,654 restricted share units vested and were converted into 19,654 ordinary shares at no cost, increasing his direct holdings to 117,244 ordinary shares.
On the same date, he sold 9,533 ordinary shares at a weighted average price of $31.6684 per share, reducing his direct holdings to 107,711 ordinary shares. According to the disclosure, these shares were sold under a pre-established Rule 10b5-1 trading plan and were required to cover tax withholding obligations from the RSU vesting.
Footnotes add that each restricted share unit represents a right to receive one ordinary share or its cash value, and that the RSU grant from March 5, 2025 vests in four equal annual installments through March 5, 2029.
Teva Pharmaceutical Industries EVP, Europe Commercial Daniell Richard reported equity award activity and a share sale. On March 5, 2026, he exercised 17,295 restricted share units for 17,295 ordinary shares at no cost, as part of a previously granted award. The same day, he sold 17,295 ordinary shares in open-market transactions at a weighted average price of $31.6684, under a Rule 10b5-1 trading plan adopted on November 10, 2025, and in connection with the vesting of the units, including shares sold to cover tax withholding obligations. Following these transactions, he directly holds 85,755 ordinary shares and 51,887 restricted share units.
TEVA PHARMACEUTICAL INDUSTRIES LTD officer Jover Placid reported restricted share units vesting and related share sales. On March 5, 2026, 14,150 restricted share units were exercised into 14,150 ordinary shares at
The same day, he sold 14,150 ordinary shares at a weighted average price of
Teva Pharmaceutical Industries interim chief legal officer Brian Savage reported equity compensation activity involving restricted share units and ordinary shares. On March 5, 2026, 3,580 restricted share units were converted into 3,580 ordinary shares at a stated price of $0.00 per share, reflecting a vesting event rather than a market purchase. On the same date, he sold 1,127 ordinary shares at a weighted average price of $31.6684 per share, with the shares sold in multiple trades between $31.26 and $32.34. According to the disclosure, these shares were required to be sold to cover tax withholding obligations arising from the vesting of the restricted share units.